FDA 483 - Uptown Research Institute - April 13, 2018

Uptown Research Institute, a biopharmaceutical clinical facility in Chicago, IL, was inspected by the FDA. The inspection revealed a significant issue regarding the retention of reserve samples for investigational products. Specifically, the facility failed to retain reserve samples from multiple shipments of investigational product during a specific protocol.